Document Detail

Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine.
MedLine Citation:
PMID:  23380428     Owner:  NLM     Status:  Publisher    
Objectives: To assess the bioequivalence of two Tizanidine 4 mg tablet formulations (Tizanidine® of the Pharma International company, as test product, and Sirdalud® of Novartis as a reference product), and to investigate possible effects of smoking on pharmacokinetics of tizanidine. Methods: A single-blind, randomized, single dose, two treatment, two-period, two-sequence, crossover bioequivalence study with 1 week washout period in 36 healthy volunteers. The drug was administered with 240 ml of water after 10-hour overnight fasting. After dosing, serial blood samples were collected for a period of 14 hours. Plasma harvested from blood was analyzed for tizanidine by a newly developed method using HPLC coupled with an MS/MS detector. The limit of quantitation of tizanidine was 0.080 ng/ml. Matrix-based calibration curves were linear over the range 0.080 - 8.00 ng/ml for tizanidine. The between- day coefficient of variation for quality control samples was less than 10%. Results: The average bioavailability measures and pharmacokinetic parameters of the two tizanidine tablets were as follows: peak plasma concentration, Cmax, was 1.21 ± 0.84 ng/ml and 1.28 ± 1.11 ng/ml for Tizanidine PIC® and Sirdalud®, respectively. The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours. The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively. The mean residence time (MRT) values were 2.16 ± 0.693 hours and 2.33 ± 0.65 hours. The 90% confidence intervals for test/reference ratio of Cmax, AUC0→last and AUC0→∞ were found within the acceptable limits of 0.00 -125.00%, consequently no significant difference was found between the test and reference. Conclusion: Based on the pharmacokinetic and statistical results, it was concluded that; Tizanidine PIC® 4 mg tablets is bioequivalent to Sirdalud® 4 mg tablets of Novartis and smoking decreases Cmax and AUC of tizanidine.
Mutasim Al-Ghazawi; Mamoun Alzoubi; Bashar Faidi
Related Documents :
22883608 - Use of the dietary supplement 5-aminiolevulinic acid (5-ala) and its relationship with ...
20386358 - Therapeutic drug monitoring for busulfan in plasma during conditioning chemotherapy for...
19730278 - An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.
20084538 - Supporting the recommended paediatric dosing regimen for rufinamide in lennox-gastaut s...
2891368 - Non-invasive instrumental techniques to detect terfenadine and temelastine induced supp...
9488258 - Effect of delayed treatment with recombinant human granulocyte colony-stimulating facto...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-5
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  -     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of sevoflurane and propofol on cultured bone-marrow mesenchymal stem cells of rats.
Next Document:  Bioequivalence study of a novel orodispersible tablet of meloxicam in a porous matrix after single-d...